Provided by Tiger Trade Technology Pte. Ltd.

TuHURA Biosciences, Inc.

2.04
+0.03101.54%
Volume:107.69K
Turnover:214.90K
Market Cap:129.76M
PE:-3.76
High:2.05
Open:2.01
Low:1.98
Close:2.01
52wk High:3.43
52wk Low:0.4100
Shares:63.58M
Float Shares:39.66M
Volume Ratio:2.36
T/O Rate:0.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5428
EPS(LYR):-0.6272
ROE:-161.39%
ROA:-58.43%
PB:7.12
PE(LYR):-3.25

Loading ...

TuHURA Biosciences CEO Bianco to Present at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 08

Tuhura Biosciences Draws $1.5 Million from Parkview Holdings Revolving Credit Facility

Reuters
·
Sep 05

Analysts’ Top Healthcare Picks: CVS Health (CVS), TuHURA Biosciences (HURA)

TIPRANKS
·
Aug 27

Tuhura Biosciences Draws $650,000 from Parkview Revolving Credit Facility

Reuters
·
Aug 22

Tuhura Biosciences Holds Annual Shareholder Meeting

Reuters
·
Aug 20

TuHURA Biosciences Price Target Maintained with a $9.00/Share by Citizens

Dow Jones
·
Aug 18

TuHURA Biosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 15

TuHURA Biosciences Q2 EPS $(0.14) Beats $(0.15) Estimate

Benzinga Earnings
·
Aug 14

Tuhura Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
Aug 14

Press Release: TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Dow Jones
·
Aug 14

Tuhura Biosciences Draws $650,000 from Parkview Revolving Credit Facility

Reuters
·
Aug 14

TuHURA Biosciences Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview

Reuters
·
Aug 13

Tuhura Biosciences Releases Corporate Deck Outlining Strategy to Tackle Cancer Immunotherapy Resistance

Reuters
·
Aug 12

Tuhura Biosciences Draws $1.5 Million from Parkview Revolving Credit Facility

Reuters
·
Jul 30

Tuhura Biosciences Draws $1.9 Million from Parkview Revolving Credit Facility

Reuters
·
Jul 08

Tuhura Biosciences Announces Annual Shareholder Meeting Webcast

Reuters
·
Jun 27

Tuhura Biosciences announces 2026 annual shareholder meeting

Reuters
·
Jun 18

TuHURA Biosciences Files New Drug Application for Evaluation of Antibody to Treat Subsets of AML

MT Newswires Live
·
Jun 15

TuHURA Biosciences files FDA IND for TBS-2025 VISTA antibody in AML, blood cancers

Reuters
·
Jun 15

Tuhura Biosciences - Targets Initiation of Phase 1B/2 Study in Second Half of 2026

THOMSON REUTERS
·
Jun 15